Vanguard Portfolio Management
CRSP icon

Vanguard Portfolio Management’s CRISPR Therapeutics CRSP Stock Holding History

Vanguard Portfolio Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.4M Buy
648,713
+101,887
+19% +$5.37M ﹤0.01% 1811
2026
Q1 		$26M Buy
+546,826
New +$28.8M ﹤0.01% 1825

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Portfolio Management's CRSP Position: Q2 2026 in Review

Vanguard Portfolio Management increased its CRISPR Therapeutics (CRSP) stake by 19% in Q2 2026, buying an estimated $5.37M and bringing the position to 648,713 shares worth $35.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1811.

Vanguard Portfolio Management first reported a position in CRSP in Q1 2026 and has held it in 2 quarters since. 520 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Vanguard Portfolio Management held 648,713 shares of CRISPR Therapeutics worth $35.4M as of Q2 2026.
  • Vanguard Portfolio Management bought 101,887 CRISPR Therapeutics shares in Q2 2026, an estimated $5.37M.
  • CRISPR Therapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #1811 holding.
  • Vanguard Portfolio Management first reported a position in CRISPR Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 520 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.